Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT

Yusuke Tokuda, Mamoru Sakakibara, Keiichiro Yoshinaga, Shiro Yamada, Kiwamu Kamiya, Naoya Asakawa, Takashi Yoshitani, Keiji Noguchi, Osamu Manabe, Nagara Tamaki, Hiroyuki Tsutsui

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Rationale: Adaptive servo-ventilation (ASV), a novel respiratory support therapy for sleep disorders, may improve cardiac function in heart failure (HF). However, the reasons that ASV improves cardiac function have not been fully studied especially in sympathetic nervous function (SNF). The purpose of the present study was to investigate the effects of ASV therapy on cardiac SNF in patients with HF. Methods: We evaluated ASV therapeutic effects before and 6 months after ASV therapy in 9 HF patients [57.3 ± 17.3 years old, left ventricular ejection fraction (LVEF) 36.1 ± 16.7%]. We performed echocardiography, polysomnography, biomarkers, 11C-hydroxyephedrine (HED) PET as a presynaptic function marker and planar 123I-metaiodobenzylguanidine (MIBG) to evaluate washout rate. Results: ASV therapy reduced apnea-hypopnea index (AHI) and improved plasma brain natriuretic peptide (BNP) concentration. In 123I-MIBG imaging, the early heart/mediastinum (H/M) ratio increased after ASV therapy (2.19 ± 0.58 to 2.40 ± 0.67; P = 0.045). Washout rate did not change (23.8 ± 7.3% to 23.8 ± 8.8%; P = 0.122). Global 11C-HED retention index (RI) improved from 0.068 ± 0.033/s to 0.075 ± 0.034/s (P = 0.029). Conclusions: ASV reduced AHI and improved BNP. ASV might initially improve presynaptic cardiac sympathetic nervous function in HF patients after 6 months of treatment.

元の言語英語
ページ(範囲)1079-1089
ページ数11
ジャーナルJournal of Nuclear Cardiology
26
発行部数4
DOI
出版物ステータス出版済み - 8 15 2019

Fingerprint

Therapeutic Uses
Single-Photon Emission-Computed Tomography
Ventilation
Heart Failure
Brain Natriuretic Peptide
Apnea
Therapeutics
Respiratory Therapy
Polysomnography
Mediastinum
Stroke Volume
Echocardiography
Biomarkers

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

これを引用

Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT. / Tokuda, Yusuke; Sakakibara, Mamoru; Yoshinaga, Keiichiro; Yamada, Shiro; Kamiya, Kiwamu; Asakawa, Naoya; Yoshitani, Takashi; Noguchi, Keiji; Manabe, Osamu; Tamaki, Nagara; Tsutsui, Hiroyuki.

:: Journal of Nuclear Cardiology, 巻 26, 番号 4, 15.08.2019, p. 1079-1089.

研究成果: ジャーナルへの寄稿記事

Tokuda, Yusuke ; Sakakibara, Mamoru ; Yoshinaga, Keiichiro ; Yamada, Shiro ; Kamiya, Kiwamu ; Asakawa, Naoya ; Yoshitani, Takashi ; Noguchi, Keiji ; Manabe, Osamu ; Tamaki, Nagara ; Tsutsui, Hiroyuki. / Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT. :: Journal of Nuclear Cardiology. 2019 ; 巻 26, 番号 4. pp. 1079-1089.
@article{04b81aa9c4ed4a0898d0bbff657000c7,
title = "Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT",
abstract = "Rationale: Adaptive servo-ventilation (ASV), a novel respiratory support therapy for sleep disorders, may improve cardiac function in heart failure (HF). However, the reasons that ASV improves cardiac function have not been fully studied especially in sympathetic nervous function (SNF). The purpose of the present study was to investigate the effects of ASV therapy on cardiac SNF in patients with HF. Methods: We evaluated ASV therapeutic effects before and 6 months after ASV therapy in 9 HF patients [57.3 ± 17.3 years old, left ventricular ejection fraction (LVEF) 36.1 ± 16.7{\%}]. We performed echocardiography, polysomnography, biomarkers, 11C-hydroxyephedrine (HED) PET as a presynaptic function marker and planar 123I-metaiodobenzylguanidine (MIBG) to evaluate washout rate. Results: ASV therapy reduced apnea-hypopnea index (AHI) and improved plasma brain natriuretic peptide (BNP) concentration. In 123I-MIBG imaging, the early heart/mediastinum (H/M) ratio increased after ASV therapy (2.19 ± 0.58 to 2.40 ± 0.67; P = 0.045). Washout rate did not change (23.8 ± 7.3{\%} to 23.8 ± 8.8{\%}; P = 0.122). Global 11C-HED retention index (RI) improved from 0.068 ± 0.033/s to 0.075 ± 0.034/s (P = 0.029). Conclusions: ASV reduced AHI and improved BNP. ASV might initially improve presynaptic cardiac sympathetic nervous function in HF patients after 6 months of treatment.",
author = "Yusuke Tokuda and Mamoru Sakakibara and Keiichiro Yoshinaga and Shiro Yamada and Kiwamu Kamiya and Naoya Asakawa and Takashi Yoshitani and Keiji Noguchi and Osamu Manabe and Nagara Tamaki and Hiroyuki Tsutsui",
year = "2019",
month = "8",
day = "15",
doi = "10.1007/s12350-017-1132-4",
language = "English",
volume = "26",
pages = "1079--1089",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT

AU - Tokuda, Yusuke

AU - Sakakibara, Mamoru

AU - Yoshinaga, Keiichiro

AU - Yamada, Shiro

AU - Kamiya, Kiwamu

AU - Asakawa, Naoya

AU - Yoshitani, Takashi

AU - Noguchi, Keiji

AU - Manabe, Osamu

AU - Tamaki, Nagara

AU - Tsutsui, Hiroyuki

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Rationale: Adaptive servo-ventilation (ASV), a novel respiratory support therapy for sleep disorders, may improve cardiac function in heart failure (HF). However, the reasons that ASV improves cardiac function have not been fully studied especially in sympathetic nervous function (SNF). The purpose of the present study was to investigate the effects of ASV therapy on cardiac SNF in patients with HF. Methods: We evaluated ASV therapeutic effects before and 6 months after ASV therapy in 9 HF patients [57.3 ± 17.3 years old, left ventricular ejection fraction (LVEF) 36.1 ± 16.7%]. We performed echocardiography, polysomnography, biomarkers, 11C-hydroxyephedrine (HED) PET as a presynaptic function marker and planar 123I-metaiodobenzylguanidine (MIBG) to evaluate washout rate. Results: ASV therapy reduced apnea-hypopnea index (AHI) and improved plasma brain natriuretic peptide (BNP) concentration. In 123I-MIBG imaging, the early heart/mediastinum (H/M) ratio increased after ASV therapy (2.19 ± 0.58 to 2.40 ± 0.67; P = 0.045). Washout rate did not change (23.8 ± 7.3% to 23.8 ± 8.8%; P = 0.122). Global 11C-HED retention index (RI) improved from 0.068 ± 0.033/s to 0.075 ± 0.034/s (P = 0.029). Conclusions: ASV reduced AHI and improved BNP. ASV might initially improve presynaptic cardiac sympathetic nervous function in HF patients after 6 months of treatment.

AB - Rationale: Adaptive servo-ventilation (ASV), a novel respiratory support therapy for sleep disorders, may improve cardiac function in heart failure (HF). However, the reasons that ASV improves cardiac function have not been fully studied especially in sympathetic nervous function (SNF). The purpose of the present study was to investigate the effects of ASV therapy on cardiac SNF in patients with HF. Methods: We evaluated ASV therapeutic effects before and 6 months after ASV therapy in 9 HF patients [57.3 ± 17.3 years old, left ventricular ejection fraction (LVEF) 36.1 ± 16.7%]. We performed echocardiography, polysomnography, biomarkers, 11C-hydroxyephedrine (HED) PET as a presynaptic function marker and planar 123I-metaiodobenzylguanidine (MIBG) to evaluate washout rate. Results: ASV therapy reduced apnea-hypopnea index (AHI) and improved plasma brain natriuretic peptide (BNP) concentration. In 123I-MIBG imaging, the early heart/mediastinum (H/M) ratio increased after ASV therapy (2.19 ± 0.58 to 2.40 ± 0.67; P = 0.045). Washout rate did not change (23.8 ± 7.3% to 23.8 ± 8.8%; P = 0.122). Global 11C-HED retention index (RI) improved from 0.068 ± 0.033/s to 0.075 ± 0.034/s (P = 0.029). Conclusions: ASV reduced AHI and improved BNP. ASV might initially improve presynaptic cardiac sympathetic nervous function in HF patients after 6 months of treatment.

UR - http://www.scopus.com/inward/record.url?scp=85035094573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035094573&partnerID=8YFLogxK

U2 - 10.1007/s12350-017-1132-4

DO - 10.1007/s12350-017-1132-4

M3 - Article

AN - SCOPUS:85035094573

VL - 26

SP - 1079

EP - 1089

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 4

ER -